Spyre Therapeutics Reports Q2 2025 Financial Results

Spyre Therapeutics, Inc ( (SYRE) ) has released its Q2 earnings. Here is a breakdown of the information Spyre Therapeutics, Inc presented to its investors.

Spyre Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative treatments for inflammatory bowel disease (IBD) and other immune-mediated diseases through advanced antibody engineering and therapeutic combinations.

In its second quarter 2025 financial results, Spyre Therapeutics reported positive interim Phase 1 results for its TL1A antibodies and announced the initiation of the Phase 2 SKYLINE-UC study for ulcerative colitis. The company is also preparing to start the Phase 2 SKYWAY-RD study for various rheumatic diseases in the third quarter.

Key financial highlights include a cash position of $526.6 million as of June 30, 2025, with a net loss of $36.7 million for the quarter. The company has seen an increase in research and development expenses, driven by higher clinical trial costs, while general and administrative expenses remained stable. Spyre also recognized a $10 million gain from the sale of a research asset.

Spyre’s strategic focus on developing next-generation therapies is underscored by its robust pipeline, which includes promising candidates like SPY001, SPY002, and SPY003. These candidates are being evaluated for their potential to offer infrequent dosing and improved efficacy in treating IBD and rheumatic diseases.

Looking ahead, Spyre Therapeutics is well-positioned to advance its pipeline with a strong financial runway extending into the second half of 2028. The company aims to deliver multiple proof-of-concept readouts over the next two years, potentially reshaping treatment paradigms in chronic immune-mediated diseases.